Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study

Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study

BackgroundWe investigated the clinical and endoscopic features, management strategies, and outcomes of Chinese cancer patients with immune checkpoint inhibitor (ICI)-induced colitis.MethodThis single-centre retrospective study included patients who developed ICI-induced colitis and underwent endosco...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Furong Kou, Jian Li, Yanshuo Cao, Zhi Peng, Ting Xu, Lin Shen, Jifang Gong, Xicheng Wang
Format:	Artykuł
Język:	English
Wydane:	Frontiers Media S.A. 2023-11-01
Seria:	Frontiers in Oncology
Hasła przedmiotowe:	immune checkpoint inhibitor colitis endoscopy steroid infliximab rechallenge
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1285478/full

Podobne zapisy

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
od: Hamzah Abu-Sbeih, i wsp.
Wydane: (2018-09-01)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
od: Hamzah Abu-Sbeih, i wsp.
Wydane: (2019-04-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
od: Sae Ohwada, i wsp.
Wydane: (2022-06-01)

Immune checkpoint inhibitors and renal toxicity
od: F. Bocchi, i wsp.
Wydane: (2024-06-01)

Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases
od: Ocepek Andreja
Wydane: (2024-03-01)

Gut microbiome and checkpoint inhibitor colitis
od: Kanika Sehgal, i wsp.
Wydane: (2021-10-01)

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
od: Hao Chi Zhang, i wsp.
Wydane: (2019-02-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
od: Eva Zhang, i wsp.
Wydane: (2021-05-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
od: Ayaka Kaneoka, i wsp.
Wydane: (2022-02-01)

Checkpoint Inhibitor-Induced Colitis: An Update
od: Giuseppe Losurdo, i wsp.
Wydane: (2023-05-01)

Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis
od: Jiahui Cao, i wsp.
Wydane: (2024-12-01)

Management and treatment of distal ulcerative colitis
od: Andrea Calafiore, i wsp.
Wydane: (2013-12-01)

Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis
od: Huijun Xu, i wsp.
Wydane: (2024-10-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
od: Carmen Portenkirchner, i wsp.
Wydane: (2021-04-01)

Analysis of the disease activity of ulcerative colitis with and without concomitant primary sclerosing cholangitis: An investigation using a nationwide database in Japan
od: Kota Yano, i wsp.
Wydane: (2022-01-01)

The growing potential of tofacitinib in immune checkpoint inhibitor-induced colitis: identifying remaining puzzle pieces
od: Raffaele Pellegrino, i wsp.
Wydane: (2024-11-01)

Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors
od: Guoqiang PAN, i wsp.
Wydane: (2019-12-01)

INFLIXIMAB IN THE TREATMENT OF SEVERE STEROID-REFRACTORY ULCERATIVE COLITIS – A CASE REPORT
od: Darja Urlep, i wsp.
Wydane: (2004-04-01)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
od: Xue Chen, i wsp.
Wydane: (2022-05-01)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
od: Hamzah Abu-Sbeih, i wsp.
Wydane: (2018-12-01)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
od: Aaron G. Issac, i wsp.
Wydane: (2022-06-01)

Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic
od: Steph A. Pang, i wsp.
Wydane: (2023-08-01)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
od: Guanzhou Zhou, i wsp.
Wydane: (2022-10-01)

Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice
od: Clarice Ho, i wsp.
Wydane: (2024-06-01)

Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis
od: Qing Zhao, i wsp.
Wydane: (2021-09-01)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
od: Harm Westdorp, i wsp.
Wydane: (2021-10-01)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
od: Yinghong Wang, i wsp.
Wydane: (2018-05-01)

Long-term infliximab therapy for ulcerative colitis in real clinical practice
od: O V Knyazev, i wsp.
Wydane: (2016-08-01)

Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
od: Margaret Corrigan, i wsp.
Wydane: (2019-05-01)

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
od: A. López San Román, i wsp.
Wydane: (2004-06-01)

Immune checkpoint inhibitor colitis, a rising issue in targeted cancer therapy era: A literature review
od: Adiwinata Randy, i wsp.
Wydane: (2024-09-01)

Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review
od: Hao Zhang, i wsp.
Wydane: (2024-01-01)

Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis
od: Alorfi NM, i wsp.
Wydane: (2022-08-01)

Bell's palsy during rechallenge of immune checkpoint inhibitor
od: Kohji Takemura, i wsp.
Wydane: (2023-03-01)

Checkpoint inhibitor induced esophagitis with documented resolution on infliximab
od: Frank W. Chen, i wsp.
Wydane: (2020-12-01)

Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
od: Ruben Faelens, i wsp.
Wydane: (2021-10-01)

Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis
od: Kata Szemes, i wsp.
Wydane: (2020-01-01)

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
od: Robert S. Zhang, i wsp.
Wydane: (2021-03-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
od: Yasunori Murata, MD, PhD, i wsp.
Wydane: (2023-12-01)

Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
od: Wang S, i wsp.
Wydane: (2024-10-01)